Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2019-04-01 Tx date 2019-03-29 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$13,439,379
+4,479,793 vol $3.00 each |
81,713,191 | |
Filed 2019-04-01 Tx date 2019-03-29 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+2,239,897 vol |
10,679,952 | |
Filed 2019-01-31 Tx date 2019-01-31 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$6,640,194
+2,213,398 vol $3.00 each |
77,233,398 | |
Filed 2019-01-31 Tx date 2019-01-31 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+1,106,699 vol |
8,440,055 | |
Filed 2017-12-04 Tx date 2017-12-01 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+5,000,023 vol |
7,333,356 | |
Filed 2017-12-04 Tx date 2017-12-01 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$87,000,000
+60,416,667 vol $1.44 each |
75,020,000 | |
Filed 2017-06-20 Tx date 2017-06-20 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$2,399,999
+1,333,333 vol $1.80 each |
14,603,333 | |
Filed 2017-06-20 Tx date 2017-06-20 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
16 - Acquisition or disposition under a prospectus exemption
|
+1,333,333 vol |
2,333,333 | |
Filed 2015-07-24 Tx date 2015-07-20 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-07-24 Tx date 2015-07-20 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
+1,000,000 vol |
1,000,000 | |
Filed 2015-07-24 Tx date 2015-07-20 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2015-07-24 Tx date 2015-07-20 |
$RVX
Resverlogix Corp. |
Shenzhen Hepalink Pharmaceutical Co., Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$35,430,900
+13,270,000 vol $2.67 each |
13,270,000 |